Latest Cetuximab Stories
Doctors and researchers of Hospital del Mar and its research institute, the IMIM, have lead a study describing a new pharmacological resistance to cancer.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found.
Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory."
Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs.
- Withering but not falling off, as a blossom that persists on a twig after flowering.